News
1d
TipRanks on MSNGSK Expands Share Buyback Programme with New Purchase
GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a ...
With the stock currently priced at Rs 2,724.90, GlaxoSmithKline Pharmaceuticals shows significant activity in today's session ...
2d
TipRanks on MSNGSK Executives Acquire Shares Under Reward Plan
GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK plc announced the acquisition of ordinary shares by several key executives under the ...
GlaxoSmithKline LLC will pay $3 billion and plead guilty to promoting two popular drugs for unapproved uses and to failing to disclose important safety information on a third in the largest heal ...
In conclusion, GlaxoSmithKline's shares showed significant gains today, reflecting positive market sentiment and strong ...
GlaxoSmithKline's new shingles vaccine Shingrix quickly captured the market after winning FDA approval and a preferential recommendation from CDC vaccine advisers, but now strong uptake is leading ...
Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...
GlaxoSmithKline and Vir finally score $1B supply deal for COVID antibody—6 months after FDA nod Continued emergence of omicron could spark a rush of sales for GSK-Vir's antibody therapy.
CARLISLE - GlaxoSmithKline, one of the world’s largest pharmaceutical companies, confirmed Monday that it will close a manufacturing facility in Carlisle next year. Production in Carlisle will ...
Photo by Flickr user Ian Wilson Doctors will no longer be paid to speak on behalf of GlaxoSmithKline and its products, the British drug maker said Tuesday. In addition, the pharmaceutical company ...
U.K.-based pharmaceutical giant GlaxoSmithKline currently sits nearly 50% off the all-time highs it set way back in 1999. Over its 300 year history , the company has been behind some of the most ...
GlaxoSmithKline's chief executive officer said in an email to the company’s employees that Slaoui’s name would be removed from its research and development facility in Rockville, Md.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results